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ABSTRACT
Nidogen-2 (NID2) is a key component of the basement membrane that stabilizes 
the extracellular matrix (ECM) network. The aim of the study is to analyze the 
functional roles of NID2 in the pathogenesis of nasopharyngeal carcinoma (NPC) and 
esophageal squamous cell carcinoma (ESCC). We performed genome-wide methylation 
profiling of NPC and ESCC and validated our findings using the methylation-sensitive 
high-resolution melting (MS-HRM) assay. Results showed that promoter methylation 
of NID2 was significantly higher in NPC and ESCC samples than in their adjacent 
non-cancer counterparts. Consistently, down-regulation of NID2 was observed in 
the clinical samples and cell lines of both NPC and ESCC. Re-expression of NID2 
suppresses clonogenic survival and migration abilities of transduced NPC and ESCC 
cells. We showed that NID2 significantly inhibits liver metastasis. Mechanistic studies 
of signaling pathways also confirm that NID2 suppresses the EGFR/Akt and integrin/
FAK/PLCγ metastasis-related pathways. This study provides novel insights into the 
crucial tumor metastasis suppression roles of NID2 in cancers.
INTRODUCTION
Cancer is a multifactorial disease arising as a 
consequence of both genetic and epigenetic alterations 
[1]. In recent decades, there has been intensified focus 
on the study of cancer epigenetics, with the aim to better 
understand the disease and develop novel therapeutics 
targeting epigenetic changes. Aberrant promoter 
hypermethylation of tumor suppressor genes (TSGs) and/
or metastasis suppressor genes (MSGs) has been well-
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studied and is known to be a key driver of tumorigenesis 
in several cancers [2–4]. 
Nidogen-2 (NID2) encodes a secretory protein 
from the nidogen protein family [5]. The NID2 and also 
its family member, NID1, are ubiquitously present in the 
basement membrane and serve to maintain the integrity 
and stability of the basement membrane by connecting 
laminin and collagen IV networks in the extracellular 
matrix (ECM) [5, 6]. NID2 silencing was reported in many 
cancer types and the aberrant promoter hypermethylation 
is one of the most critical events detected in different 
malignancies, including gastric [7], bladder [8, 9], 
and invasive cervical [10] cancers. Detection of NID2 
methylation was proposed as a biomarker for the diagnosis 
of many cancers including non-small cell carcinoma of 
lung [11], urothelial carcinoma of urinary bladder [9, 
12, 13] and squamous cell carcinoma of oral cavity [14]. 
Furthermore, a functional study revealed that NID2-
deficient mice have higher lung metastasis upon tail vein 
injection of melanoma cells [15], suggesting a critical role 
of NID2 in suppressing the metastatic potential of cancer 
cells.
Previously, we utilized the Illumina 
HumanMethylation450 Bead Chip (HM450) to examine 
the methylome profile of two cancers of the aerodigestive 
tract of relatively high prevalence in China, namely, 
nasopharyngeal carcinoma (NPC) [16] and esophageal 
squamous cell carcinoma (ESCC). A number of TSGs 
silenced by means of promoter hypermethylation has 
already been identified in these two cancers [17–23]. They 
are confirmed by our previous functional genetics and 
epigenetics approaches. From the methylome analyses, 
NID2 was confirmed to be the top hit as a promoter 
hypermethylated gene in both NPC and ESCC. As NID2 
harbors several de novo methylated loci in the CpG 
islands, it is a potential TSG/MSG in these cancers.
Despite the substantial number of studies associating 
NID2 to different cancers, to the best of our knowledge, 
there have not been any in-depth functional studies to 
elucidate the potential suppressive role of NID2 in cancers, 
especially in NPC and ESCC. Hence, in the present study, 
we aimed to scrutinize the functional role of NID2 in these 
cancers.
RESULTS
Down-regulation of NID2 is highly associated 
with aberrant promoter hypermethylation in 
both NPC and ESCC
Our previous HM450 methylome analysis of 25 
primary NPC [16] and 17 primary ESCC (unpublished 
data) and their matched adjacent non-cancer tissues has 
shown that hypermethylation is important in these cancers. 
This is a frequent event in NPC compared to many other 
cancer types [24]. In this study, we analyzed our NPC and 
ESCC methylome data to identify candidate genes that 
are regulated by aberrant methylation. Among the genes 
that showed differential methylation, NID2 was one of 
the top candidate genes showing significant differences 
in the methylation levels between cancer and non-
cancer specimens. In both NPC and ESCC, the CpG-rich 
promoter regions of NID2 were hypermethylated, when 
compared to the matched non-cancer tissues (Figure 1A) 
(Supplementary Figure S1).
In addition to global HM450 methylome studies, 
our previous functional complementation studies utilized 
the microcell-mediated chromosome transfer (MMCT) 
approach to transfer an intact human chromosome 14 
into the tumorigenic HONE1 cell line for identification 
of TSGs [18]. A panel of tumor-suppressive microcell 
hybrids (MCHs) and tumorigenic tumor segregants (TSs) 
was established. Studies found that TSGs usually show 
up-regulation in the MCHs, while being down-regulated 
in the TSs [18]. NID2 showed significant up-regulation 
in the MCHs and down-regulation in the matched TSs 
(Figure 1B). This functional complementation study 
further supported the potential of the NID2 to function as 
a tumor suppressor or metastasis suppressor.
To evaluate the NID2 promoter hypermethylation 
in NPC and ESCC, we identified the region that showed 
distinct differential methylation in selected NPC cell 
lines, when compared to the NP cell lines (Supplementary 
Figure S2). The high-throughput methylation-sensitive 
high-resolution melting (MS-HRM) assay was used 
to assess the promoter methylation status of NID2 in 
clinical samples. We found that 74% of 50 NPC biopsies 
had a methylated NID2 promoter, while the majority of 
the adjacent non-cancer tissues remained unmethylated 
(66%) (Figure 2A). In ESCC, a trend of NID2 promoter 
hypermethylation was detected in 80% of the samples 
(Figure 2A), which was consistent with our unpublished 
ESCC methylome data using the same samples. These 
MS-HRM results further validate the clinical significance 
of the NID2 promoter hypermethylation, supporting our 
finding from the HM450. The MS-HRM results showed 
that the NID2 promoter is methylated in HONE1, HK1, 
and C666 (NPC cell lines), when compared to the 
unmethylated immortalized nasopharyngeal cell lines 
(NP69 and NP460). Similarly, the NID2 promoter is also 
methylated in the ESCC cell lines (KYSE30, KYSE150, 
and SLMT-1S1), while the NID2 promoter in NE3 and 
NE083 (immortalized esophageal cell lines) remain 
unmethylated (Supplementary Figure S3). 
The expression levels of NID2 were determined in 
paired NPC/ESCC and non-cancer biopsies to validate 
their clinical relevance. NPC [50% (37/74)] and ESCC 
biopsies [43% (12/28)] showed more than two-fold 
down-regulation of NID2 (Figure 2B). These data 
support NID2 being a potential TSG in ESCC and NPC. 
Immunohistochemical (IHC) analysis of NID2 was used to 
show protein expression levels directly in cancer tissues. 
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Representative images are shown in Supplementary Figure 
S4, in which stronger staining in the non-neoplastic glands 
of nasopharyngeal mucosa was observed in comparison 
to the staining in NPC. qPCR analysis in the cell lines 
showed that NID2 is down-regulated in 100% (7/7) 
of NPC cell lines and 80% (12/15) of ESCC cell lines 
(Figure 2C). Consistent with the MS-HRM results, NID2 
expression was lower in cell lines that had methylated 
NID2 promoter (HONE1, HK1, C666-1, KYSE30, 
KYSE150, and SLMT-1S1), when compared to the 
respective non-neoplastic immortalized cell lines with an 
unmethylated NID2 promoter.
NID2 re-expression suppresses NPC and ESCC 
cancer-associated characteristics: Clonogenic 
survival and cancer cell migration and invasion 
abilities
To confirm the effect of NID2 on both NPC and 
ESCC disease progression, NID2 was re-expressed in NPC 
(HONE1) and ESCC (KYSE30) cells. Detectable NID2 
protein was found in both cell lysates and conditioned 
media (Figure 3A). The NID2-expressing cells were then 
used for the downstream functional studies.
The clonogenic survival ability of tumor cells 
is a prerequisite for occurrence of metastasis and was 
assessed by 2D and 3D colony formation assays. NID2-
expressing HONE1 cells significantly reduced colony-
forming ability. The number of colonies formed was 
only 43.4% of the vector-alone (VA) control. KYSE30 
cells expressing NID2 only retained 38% of the colony-
forming ability (Figure 3B). The NID2-expressing cells 
were also cultured on the 3D Matrigel matrix, to mimic 
the ECM environment. They showed significant reduction 
of clonogenic survival ability. On average, the number of 
tumor spheres (≥ 100 μm) formed in NID2-expressing 
HONE1 and KYSE30 was reduced to 62% and 45%, 
respectively, of the VA control (100%) (Figure 3C). 
Previous study suggested that NID2-deficient mice 
have higher lung metastasis [15], implying a critical role 
of NID2 in suppressing cell motility and, thus, metastasis. 
We examined the ability of NID2 to inhibit in vitro 
migration in the wound healing assay. NID2 re-expression 
in both HONE1 and KYSE30 impaired migration ability, 
as seen by the delayed wound closure, when compared 
to VA control (Figure 4A). In the in vitro migration 
chamber assay, the relative migration abilities were also 
significantly lower in NID2-expressing HONE1 (68%, 
Figure 1: NID2 is identified as a candidate gene in NPC and ESCC. (A) The average methylation level of NID2 derived from 
our previous methylome data in NPC and ESCC. The vertical broken line shows the region covering the promoter CpG island (chr14: 
52534582–52536722) and the bottom figures show a close-up view of changes in methylation. Methylation level is presented as β value (β 
= M/(U+M+100), M: signal intensity of the methylated allele, U: signal intensity of the unmethylated allele). The y-axis shows the average 
methylation level in tumors (orange line) and non-cancer controls (blue line), respectively. Within this region, the methylation levels in 
multiple CpG sites of both NPC and ESCC patients are consistently higher than those of non-cancer controls, with adjusted p value < 0.05 
estimated by LIMMA analysis using the transformed β values as previously described [16]. Significance level of each selected probes were 
shown in Supplementary Figure S 1. (B) MMCT of chromosome 14 was previously performed using HONE1 as the recipient cell line 
[18]. qPCR analysis of tumor-suppressive microcell hybrids (MCHs) and their tumor segregant (TS) cell lines, which are no longer tumor-
suppressive, showed that NID2 expression was down-regulated in all five TS cell lines, when compared to their respective MCHs. Asterisk 
(*) indicates samples with more than two-fold differences compared to its MCHs.
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*p < 0.05) and KYSE30 (56%, *p < 0.05) (Figure 4B). In 
Matrigel-coated invasion chambers, re-expression of NID2 
led to significant reduction in the relative invasiveness of 
HONE1 (67%, *p < 0.05) and KYSE30 (58%, **p < 0.01) 
(Figure 4B). These results confirmed the functional role 
of NID2 in suppression of in vitro cancer cell migration 
and invasion.
NID2 negatively regulates the cancer-related 
EGFR/Akt and Integrin/FAK/PLCγ pathways 
associated with ECM protein signaling
Studies of how NID2 may be involved in different 
cancer signaling pathways are still lacking. The Human 
Phospho-Kinase Antibody Array was utilized to explore 
the possible cancer signaling pathways that may be 
affected by NID2. NID2 re-expression significantly 
reduced the phosphorylation levels of several cancer-
related molecules in the key ECM protein-related 
pathways, including FAK (Y397) and PLCγ (Y783) of 
the integrin signalling pathways and Akt (T308) of the 
epidermal growth factor receptor (EGFR) downstream 
signaling pathways (Figure 5A). 
Cell-ECM interactions are crucial in regulating 
the behavior of cells. The signal transduction cascade 
induced by alteration in the ECM is mediated by integrins 
and EGFR. Members of the integrin-mediated ECM 
signaling pathways such as FAK and PLCγ have reduced 
phosphorylation upon NID2 expression, suggesting an 
overall inactivation of integrin signaling (Figure 5B). 
Western blot analyses on NID2-expressing cells validate 
our findings in the human phosphorylation array. Previous 
study suggested that the inhibition of EGFR/Akt signalling 
significantly suppresses cancer cell metastasis, including 
NPC metastasis [25]. NID2 re-expression in cancer cells 
revealed attenuated EGFR activity. There were reduced 
levels of the phosphorylated form of EGFR at various 
tyrosine sites (Y992, Y1068, Y1086, Y1148, and Y1173) 
(Figure 5C). NID2 also inhibited the downstream Akt 
pathway. Reduction in phospho-Akt levels was observed 
at T308 and Y473 sites (Figure 5C). These results support 
the crucial role for NID2 in the suppression of these 
cancer-associated signaling pathways.
NID2 potently inhibits in vivo metastasis, but 
does not affect in vivo subcutaneous tumor 
growth
Previous study showed that NID2-deficient 
mice have a higher lung metastasis frequency, when 
intravenously injected with melanoma cells [15]. In this 
study, the functional role of NID2 in the suppression of 
Figure 2: Validation of NID2 promoter hypermethylation and its down-regulation in NPC and ESCC. (A) In 37 of 50 
(74.0%, p-value = 0.0001) NPC biopsies, the NID2 promoter hypermethylation was observed. The NID2 promoter was methylated in 12 
of 15 (80.0%, p-value = 0.1281) ESCC biopsies, as shown by MS-HRM results. (B) qPCR analysis showed that expression of NID2 is 
down-regulated in 50% (37/74) of NPC biopsies and 43% (12/28) of ESCC biopsies showing more than two-fold down-regulation of NID2 
expression. (C) All 7 NPC cell lines showed down-regulation of NID2 expression, after normalization to the immortalized nasopharyngeal 
cell line. 75% of the ESCC cell lines (12 of 16) have decreased NID2 expression, when compared to the immortalized normal esophageal 
epithelial cell line. The housekeeping gene GAPDH was used as an internal control for all qPCR analysis and the asterisks (*) indicate 
samples with more than two-fold up-regulation (> 2.0) or down-regulation (< 0.5).
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Figure 3: NID2 inhibits 2D and 3D clonogenic survival. (A) Western blot analysis confirmed re-expression of NID2 in selected 
NPC (HONE1) and ESCC (KYSE30) cell lines, which have down-regulated NID2 expression. Over-expression of NID2 was detected in 
cell lysates, as well as being secreted into the conditioned media. Coomassie blue staining of total protein was used as a loading control 
for the conditioned media. (B) 2D colony formation assays of HONE1 and KYSE30 cells. Re-expression of NID2 significantly reduced 
their colony-forming abilities to around 40% (**p < 0.01). Data shown are the mean from three independent experiments ± S.D. (C) In 3D 
Matrigel culture, cells re-expressing NID2 resulted in significantly lower numbers of tumor spheres (≥ 100 μm), when compared to the VA 
in both NID2-expressing HONE1 and KYSE30 cells (**p < 0.01). Data shown are the mean from three independent experiments ± S.D.
Figure 4: NID2 suppresses cell migration and invasion. (A) Cell migration ability was evaluated by the wound healing assay. 
Microscopic images were taken at 0th hour and 24th hour to monitor the extent of wound closure. Both NID2-expressing HONE1 and 
KYSE30 cells showed impaired wound healing ability, when compared to the VA controls (*p < 0.05). (B) Representative fields of migrated 
or invaded cells at 100x magnification. Re-expression of NID2 resulted in significant reduction of migration and invasion abilities of 
HONE1 and KYSE30 cells (*p < 0.05, **p < 0.01). Data shown are the mean from three independent experiments ± S.D.
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in vivo metastasis was examined by intrasplenic injection 
of metastatic cancer cells. The NID2-expressing cells 
and the VA control were used for intrasplenic injection 
into nude mice [25] and the in vivo metastasis status was 
monitored weekly by the Xenogen live animal imaging 
system (Figure 6A). The nude mice were euthanized at 
week 3 post-injection, followed by necropsy. Using the 
highly metastatic HONE1-Luc cells, tumor nodules 
were clearly visible in 90% of the livers from the VA 
group (Figure 6B). The mice from the VA group showed 
a high metastasis rate to the liver (10 of 11 mice; 90%), 
whereas in the NID2 group, there were no metastasized 
tumors observed in the excised livers (0 of 12 mice; 0%; 
p-value = 0.0001) (Figure 6C). The results were further 
validated by H&E staining. Representative H&E staining 
images of metastatic liver tumor nodules and metastasis-
negative samples are shown (Figure 6D). These results 
provide strong evidence for a functional role of NID2 in 
the inhibition of the in vivo metastasis.
In order to eliminate the possibility that the 
difference in the ability for metastasis is induced by 
the inhibition of the in vivo tumor growth by NID2, the 
in vitro cell proliferation assay and in vivo subcutaneous 
nude mouse tumorigenicity assay were performed. Results 
suggested that NID2 re-expression was unable to induce 
significant changes in both the in vitro cell proliferation 
and in vivo tumorigenicity of the cancer cells (Figure 
7A and 7B). These results provide further evidence in 
support of NID2 playing an important role in metastasis 
suppression, despite it not affecting primary tumor growth.
DISCUSSION
In this study, we examined the methylome of 
NPC and ESCC tumors and successfully identified a 
hypermethylated gene, NID2, which is a potential TSG/
MSG. This possibility was further supported by our 
previous chromosome 14 MMCT NPC study. Frequent 
allelic deletions of chromosome 14q have also been 
observed in both NPC [26] and ESCC [27], where NID2 
gene is mapped. NID2 was also consistently found to be 
hypermethylated in several other cancers [7–14, 28–30].
NID2 is an ECM protein and an important member 
of the basement membrane. Deregulated ECM signaling 
Figure 5: NID2 suppresses important signaling pathways in cancer. (A) Phosphorylation study of NID2-expressing cells using 
the Human Phospho-Kinase Antibody Array. Reduced phosphorylation of (1) FAK (Y397), (3) STAT1 (Y701), (4) Akt (T308), (5) STAT4 
(Y693), (6) RSK1/2/3 (S380/S386/S377), and (7) PLCγ (Y783), and increased phosphorylation of (2) ERK1/2 (T202/Y204, T185/Y187) 
in the NID2-expressing cells was observed. The bar chart shows the relative quantification of the array data, normalized to VA control (*p 
< 0.05). Blue arrows indicated significant changes that were further validated using Western blot. (B) Re-expression of NID2 in HONE1 
and KYSE30 cell lines resulted in reduced phosphorylation levels of FAK (Y397/Y925) and PLCγ (Y783), as shown by representative 
Western blot images. (C) The levels of phosphorylated EGFR at five tyrosine sites (Y992/ Y1068/Y1086/Y1148/Y1173) were decreased 
by the re-expression of NID2 in both HONE1 and KYSE30. Downstream Akt pathways were also suppressed by NID2, as shown by the 
reduced phosphorylation level of Akt (T308/S473). Numbers at the bottom of each band represent the relative quantification of the protein 
level, normalized to the VA control. 
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Figure 6: NID2 significantly suppresses cancer metastasis in vivo. (A) Representative images of nude mouse bioluminescent 
imaging to monitor the extent of in vivo metastasis after intrasplenic injection (B) Lesions on liver were apparent to the naked eye, for those 
in which metastasis occurred, and are indicated with arrows. None of the excised livers in the NID2 group showed overt tumor lesions. (C) 
Comparison of in vivo metastasis ability between the two groups revealed a significantly strong suppression of liver metastasis in the NID2 
group, in which 0 of 12 mice developed tumors, while in contrast, 10 of 11 mice in the vector control group developed liver metastasis 
(**p < 0.0001) (D) Histological examination of the excised livers confirms the presence of multiple tumors. Representative H&E stained 
images of mouse liver from the VA group with metastatic undifferentiated carcinoma and mouse liver from NID2-expressing group, with 
no observable tumor. 
Figure 7: NID2 does not affect cell proliferation in vitro and tumor growth in vivo. (A) In vitro cell proliferation was assessed 
using the MTT assay. Re-expression of NID2 did not affect HONE1 and KYSE30 cell growth. (B) Nude mouse subcutaneous injection 
was used to assess the effect of NID2 on in vivo tumor growth. Using both HONE1 and KYSE30, there were no significant differences in 
the tumor growth kinetics between the NID2-expressing and VA groups. Each data point was plotted as an average tumor volume of six 
tumor sites ± S.E.M. 
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caused by a disrupted basement membrane network 
is widely recognized as a hallmark of cancer [31]. The 
dynamic and complex cell-matrix signal transduction 
orchestrates cell behavior, which functionally impacts its 
adhesion, migration, differentiation, and proliferation [32, 
33]. Previously, we identified several TSGs in NPC and 
ESCC that are either encoding ECM proteins (FBLN2 [21] 
and LTBP2 [22, 34, 35]) or proteases involved in ECM 
remodelling (ADAMTS9 [36, 37] and MMP19 [38]). The 
re-expression of these TSGs was reported to suppress NPC 
and/or ESCC cell migration, invasiveness, angiogenesis, 
and in vivo tumor growth [21, 22, 34–36]. 
The colony formation assay is commonly used 
to assess the in vitro clonogenic survival ability, which 
is a critical prerequisite for cancer cells to colonize a 
secondary site during metastasis [39, 40]. In this study, 
concordance with the hypothesis that NID2 is a MSG, 
NID2 re-expression significantly suppresses the colony 
formation of both NPC and ESCC cells, in both 2D and 
3D Matrigel culture. Furthermore, NID2 also plays a 
significant role in impairing the migration and invasion 
abilities of the cancer cells. These in vitro findings support 
our subsequent in vivo results. NID2-expressing NPC 
cells significantly inhibit metastasis formation in the liver. 
Collectively, these results confirm the role of NID2 as a 
potent suppressor of metastasis in NPC.
Metastasis is a complex process that involves 
dynamic degradation and remodelling of the ECM. 
There is increasing recognition of the important role of 
the ECM-defined tumor microenvironment in tumor 
initiation and progression. This is exemplified by the 
discovery of how ECM collagen regulates ECM stiffness 
and triggers a signaling network to promote breast cancer 
cell invasion and metastasis [41, 42]. Similarly, Mokkapati 
et al. reported higher lung metastases for melanoma cells 
in NID2-null mice [15]. The absence of this important 
component of the vascular basement membrane facilitated 
the transmigration of melanoma cells and resulted in 
a higher metastasis frequency to the lung [15]. This is 
consistent with findings in this current study, where the 
re-expression of NID2 significantly inhibited NPC cell 
metastasis to the liver. The abilities of tumor cells to 
survive in the blood circulation, to extravasate and to 
colonize the distant metastatic organ are the key steps 
governing metastasis, which can all be evaluated in our 
in vivo metastasis assay. In our study, NID2-expressing 
cells have markedly lost these abilities and, as a result, 
none of the mice in the NID2 group had distant metastasis. 
In contrast, the VA group had a very high percentage of 
distant metastasis (90%), with obvious tumor nodules on 
the liver. We hypothesize that the tumor microenvironment 
of NID2-expressing cells in the circulation or liver 
disfavors the processes of extravasation and colonization 
during the later cascade of metastasis, leading to the 
observation of distinctive difference in metastatic 
outcome, when compared to the control cells. Thus, the 
down-regulation of NID2 by promoter hypermethylation 
appears to be a key event leading to cancer metastasis.
As a secretory basement membrane protein 
constituting the tumor microenvironment, changes 
in NID2 protein levels can lead to a change in the 
ECM signaling cascade to redefine cell fate. Integrin 
molecules are the major receptors mediating extracellular 
signal transduction into regulating cellular responses 
such as migration and proliferation [32, 43–45]. It is 
conventionally believed that upon ECM ligand activation, 
integrin clusters, and signaling complexes are formed at 
the focal adhesions, including FAK, Src, PI3K, and PLCγ 
[46, 47]. Among these, activation of the FAK pathway 
is known to confer a survival advantage and promote 
cell motility [43, 47]. In our study, results from both the 
Human Phospho-Kinase Antibody Array and Western blot 
show reduction of phosphorylation in integrin-related 
downstream molecules such as FAK and PLCγ, when 
NID2 is re-expressed. The EGFR/PI3K/Akt pathways 
are important players in both NPC [25, 48] and ESCC 
[49, 50]. Previous study suggested that inhibition of the 
Akt signalling pathway greatly inhibits in vivo metastasis 
[25]. Overexpression of EGFR and/or up-regulation of 
EGFR phosphorylation signaling are common in both 
cancers [25, 48–50], with Akt playing a central role as the 
downstream effector molecule [48]. Interestingly, EGFR 
signaling pathways can also be activated by crosstalk 
with the integrin pathways, in which they may act 
synergistically to promote tumorigenesis and metastasis 
[51, 52]. 
In this current study, we found that restoration of 
NID2 expression has a negative regulatory role on both 
EGFR and integrin signaling pathways. We propose that 
NID2 elicits its in vitro migration/invasion suppression 
and in vivo metastasis inhibition effects via the negative 
modulation of these two oncogenic pathways. Further 
in-depth mechanistic study of how NID2 intervenes with 
these signaling networks is warranted to further elucidate 
our understanding of its ability to suppress metastasis. 
In conclusion, NID2 plays an important role as an ECM 
protein defining the tumor microenvironment and is 
involved in metastasis suppression.
MATERIALS AND METHODS 
Cell culture
All NPC cell lines (HONE1, HK1, CNE1, CNE2, 
HNE1, SUNE1, and C666) and the immortalized 
nasopharyngeal epithelial cell lines (NP460 and NP69) 
were cultured as previously described [53–57]. The 
HONE1-Luc used for the intrasplenic injection was 
cultured as previously demonstrated [25]. The panel 
of tumor-suppressive microcell hybrids (MCHs) and 
tumorigenic tumor segregants (TSs) was established in an 
earlier chromosome 14 microcell-mediated chromosome 
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transfer study and cultured as previously described [18]. 
The ESCC cell lines (KYSE30/70/140/150/180/270/
410/450/510/520, SLMT-1S1, EC1, EC18, HKESC2, 
and T.Tn6) and the immortalized esophageal epithelial 
cell lines (NE3 and NE083) were cultured, as detailed 
[58, 59]. The 293FT cell line was purchased from 
Invitrogen (Carlsbad, CA, USA) and cultured as 
recommended. All cell lines were tested for mycoplasma. 
Clinical samples
For methylation-sensitive high-resolution melting 
(MS-HRM) analysis, 50 NPC biopsies and matched 
adjacent non-cancer tissues were collected in Hong Kong 
between 2010–2013. These specimens were a subset of our 
previous methylation biomarker study [60]. A total of 17 
archived paired ESCC biopsies were obtained from Tuen 
Mun Hospital and Queen Mary Hospital for the ESCC 
methylome study (unpublished) and 15 of the informative 
cases were used in MS-HRM. Specimens utilized for the 
qPCR were as previously described [18, 59].
Extraction and bisulfite conversion of genomic 
DNA
Genomic DNA from NPC and ESCC biopsies was 
extracted using TRIzol (Invitrogen, Carlsbad, CA, USA), 
as described previously [60]. Genomic DNA was extracted 
from cell lines using a previously published phenol-
chloroform extraction protocol [61]. A quantity of 500 ng 
genomic DNA was used as input for bisulfite conversion 
[62]. Bisulfite-converted DNA was then precipitated with 
ethanol and resuspended in 50 μl of 10 mM Tris-HCl 
(pH 8.5).
Identification of putative NID2 promoter
Sequences within 200 base pairs of the transcription 
start site (TSS200) and 5′ untranslated region (5′UTR) 
sequences in the first exon of NID2 were retrieved 
from the UCSC browser (GRCh37: chr14: 52535485-
52536146). Putative promoter sequences were identified 
using PROSCAN (http://www-bimas.cit.nih.gov/molbio/
proscan/) (Supplementary Figure S5). Using MethPrimer 
[63], a CpG island of 324bp was identified and a pair of 
primers was designed to amplify a 293bp region within 
this island for clonal bisulfite sequencing. The primers 
used were 5′- TAGTTTGTTGGGTGGGTTTG -3′ and 5′- 
CCTTCCTACAAAAACTAATCCCC-3′ (Supplementary 
Figure S6). 
Methylation-sensitive high-resolution melting 
(MS-HRM)
Primers for MS-HRM were designed based 
on guidelines from Wodjaz et al. (2008) [64]. 
An 88bp region containing 12 CpG sites was 
amplified using the following MS-HRM primers: 
5′- CGCGGAGAGTGGGTTGGAGGT -3′ and 5′- 
ACCACCCGATCCCCCTCCATACT -3′. MS-HRM 
analysis was carried out using the Light Cycler 480 
System (Roche), as described [60]. 
Immunohistochemical (IHC) analysis
IHC staining was performed on NPC biopsies 
using anti-NID2 (SAB1409003) polyclonal antibody 
from Sigma-Aldrich (St Louis, MO, USA), following 
procedures as previously reported [65].
Plasmid construction and lentiviral infection
The full-length human NID2 gene, in pCEP-Pu-
NID2 vector, was provided by Dr. T Sasaki (Friedrich-
Alexander-University, Germany). The NID2 open reading 
frame (ORF) was cloned into a lentiviral expression 
vector, pLenti6/UbC/V5-DEST (Invitrogen, Carlsbad, 
CA, USA). The vector-alone (VA) and NID2 constructs 
were co-transfected with the packaging vector, psPAX2 
and the envelope vector, pMD2.G, at a ratio of 4:3:1 
(8μg/6μg/2μg). The human embryonic kidney cell line 
293FT was used for virus packaging. Viruses collected 72 
hours post-transfection were filtered and stored at -80°C 
until use. For in vivo study, the NID2 ORF was cloned into 
the pLVX-EF1α system and stably transduced cell lines 
were established.
Quantitative RT-PCR analysis
Total RNAs were extracted using TRIzol 
(Invitrogen, Carlsbad, CA, USA). The cDNA was 
synthesized using M-MLV Reverse Transcriptase (USB, 
Cleveland, OH, USA) with 1μg of total RNAs. Expression 
levels of NID2 were measured using quantitative RT-
PCR with the Applied Biosystems Step-One Plus 
platform. NID2 and GAPDH Taqman probes were used. 
Up-regulation is defined as having a fold difference > 
2.0, while down-regulation is defined as having a fold 
difference < 0.5.
Western blot
Cells were grown to 60–80% confluence and 
conditioned media/lysates were harvested. Conditioned 
media was spun down at 4°C using 10K Amicon 
centrifugal filter (Millipore, Bedford, MA, USA) to 
concentrate the secreted protein. Cells were lysed using 
RIPA buffer and Western blot analyses were performed as 
previously described [17]. Antibodies used in this study are 
summarized in Supplementary Table S1. Quantification of 
the bands was performed using ImageJ software (National 
Institutes of Health, Bethesda, MD USA) [66].
Oncotarget78868www.impactjournals.com/oncotarget
Colony formation assay
The 2D and 3D colony formation assays were 
performed as described by Kan et al. [35] and Wong et 
al. [67], respectively. For 3D colony formation assay, 
the 12-well plate was coated with one layer of Matrigel 
(BD Biosciences, San Jose, CA, USA). Transduced cells 
(2 × 104) were seeded onto the Matrigel and allowed to 
grow for a week until tumor spheres became apparent. 
Ten images of different microscopic views at 100× 
magnification were captured and tumor spheres with 
diameters above 100 μm were counted. 
Wound healing assay
The wound healing assay was carried out as reported 
previously [65]. Wound closure percentage was calculated 
using the formula: (migrated distance at 24 hour ÷ initial 
wound width) × 100. For relative migration ability, the 
percentage wound closure of NID2-expressing cells was 
normalized to that of vector control.
Transwell migration and invasion assays
The transwell assays were performed as described 
previously [35, 56]. Briefly, 2 × 105 cells were seeded 
in serum-free medium in the top chamber of the BD 
BioCoat migration insert or Matrigel invasion insert (BD 
Biosciences, St Jose, CA, USA), fitted with an 8μm pore 
membrane. Culture medium enriched with 10% serum 
was used as chemoattractant in the bottom chamber. At 
the end of assay (24–48 hours), migrated and invaded cells 
were fixed and stained with crystal violet. Five different 
microscopic fields (100× magnification) of the chambers 
were taken and quantification was with ImageJ software 
(NIH, Bethesda, MD USA). 
Human phospho-kinase antibody array
The protein lysates from the vector-alone (VA) 
and NID2-expressing HONE1 cells were used for the 
Human Phospho-Kinase Antibody Array (R&D Systems, 
Minneapolis, MN, USA), as described [25]. Quantification 
of the array data was performed using ImageJ software 
(NIH, Bethesda, MD USA) [66].
Cell proliferation assay
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide) assay was utilized for the in vitro cell 
proliferation assay as previously described [56]. A total of 
2 × 104 cells was seeded in 96-well plates and absorbance 
of MTT was measured daily for five consecutive days at 
570 nm.
In vivo tumorigenicity and metastasis assays
In vivo nude mouse subcutaneous injection was 
performed as described previously [57]. Briefly, 1 × 107 
and 1 × 106 cells of transduced HONE1 and KYSE30 
cells, respectively, were inoculated subcutaneously into 
the flanks of female BALB/cAnN-nu (nude) mice. Tumor 
growth was monitored weekly with the use of digital 
calipers. 
Nude mouse intrasplenic injection was conducted 
for the in vivo metastasis assay as described [25]. A 
total of 1 × 106 cells of pLVX-EF1α (VA)/pLVX-NID2 
transduced HONE1-Luc was injected into the spleen of 
the mice following laparotomy. Mice were monitored 
weekly by detecting the bioluminescent signals upon 
intraperitoneal injection of D-luciferin as described [25]. 
Live bioluminescent imaging was performed using the 
IVIS Spectrum In vivo Imaging System (PerkinElmer, 
Norwalk, CT, USA), available at the Core Facility of 
Li Ka Shing Faculty of Medicine, The University of 
Hong Kong. At the third week post-inoculation, mice 
were sacrificed and necropsy was performed. The livers 
of the mice were excised and examined for presence 
of metastasized tumors. All the animal experiments 
were conducted with valid license from the Department 
of Health, Hong Kong S.A.R. and approved by the 
Committee on the Use of Live Animals in Teaching and 
Research (CULATR) of The University of Hong Kong.
Paraffin embedding and Hematoxylin and Eosin 
(H&E) staining
Excised tissues were paraffin embedded and H&E 
stained as described [25].
Statistical analysis
Chi-square test or Fisher’s exact test (if any cell size 
was less than 5) was used in the MS-HRM analysis of 
biopsies and the in vivo metastasis assay. Student’s t-test 
was utilized for statistical analyses for other experiments 
unless stated otherwise. P-values below 0.05 were 
considered statistically significant.
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